Sweet's syndrome triggered by COVID-19

Authors

  • María Gimena Polimeni Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Patricia Silvia Della Giovanna Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Diego Martín Loriente Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina
  • Carmen Tatiana Alfaro Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v31i2.2873

Keywords:

Sweet's syndrome, acute myeloid leukemia, COVID-19

Abstract

Sweet syndrome or acute febrile neutrophilic dermatosis is a rare and probably underdiagnosed entity. In recent years, cases of Sweet syndrome met both with COVID-19 infection and with its vaccines. We report the first case in the national literature of a patient with a history of acute myeloid leukemia who presented Sweet syndrome secondary to SARS-CoV-2 disease.

Author Biographies

María Gimena Polimeni, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

Third-Year Medical Trainee, Dermatology Specialist Program, University of Buenos Aires (BA)

Patricia Silvia Della Giovanna, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

Dermatologist, Head of the Dermatology Service

Diego Martín Loriente, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

Dermatologist

Carmen Tatiana Alfaro, Professor Alejandro Posadas National Hospital, Province of Buenos Aires, Argentina

Pathologist

References

I. Strong J, Zhou AE, Alkaabba F, Soldin D, et ál. A case of acute myeloid leukemia-associated necrotizing Sweet syndrome. Dermatol. 2022;14:339-343.

II. Orfaly VE, Shakshouk H, Heath M, Hamilton A, et ál. Sweet syndrome: a review of published cases. Dermatology. 2023;239:664-669.

III. Uy GL, Aldoss I, Foster MC, Sayre PH, et ál. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751-762.

IV. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016;107:369-378.

V. Chelly I, Zehani A, Mbazaa A, Azouz H, et ál. Syndrome de Sweet: étude rétrospective de 47 cas. Rev Med Interne. 2013;34:197-201.

VI. Fonseca GSD, Pinto AFDA, Silveira SCF, Silva JHDAE, et ál. Sweet's syndrome during induction chemotherapy for acute myeloid leukemia: case report and mini review. Hematol Transfus Cell Ther. 2021;43:374-376.

VII. Merlant M, Lepelletier C, Battistella M, Vignon-Pennamen MD, et ál. Acute myeloid leukemia and myelodysplastic syndrome-associated Sweet syndrome. A comparative multicenter retrospective study of 39 patients. J Am Acad Dermatol. 2021;84:838-840.

VIII. Agharbi FZ, Oqbani K, Allaoui A, Chikhaoui I, et ál Sweet syndrome in post-COVID-19 infection: a case report. Travel Med Infect Dis. 2021;44:102188.

IX. Ferea CR, Mihai SN, Balan G, Badescu MC, et ál. Sweet Syndrome associated with myelodysplastic syndrome. A review of a multidisciplinary approach. Life (Basel). 2023; 13:809.

X. Joshi TP, Dokic Y, Verstovsek G, Rosen T. A case of filgrastim-induced neutrophilic dermatosis of the dorsal hands in a patient with Felty syndrome. Dermatol Online J. 2023;29.

Downloads

Published

2025-08-01

Issue

Vol. 31 No. 2 (2025): May-August

Section

Clinical Cases

License

Copyright (c) 2025 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor